News | 22 April 2023
CCI approves Berhyanda's acquisition of Suven Pharma
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
SÜDPACK is setting standards in terms of both performance and sustainability
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Showcased digital innovations: MyPKFit, SYNAPSE and Athena at the G20 Health Working Group Meeting
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
This plant adds around 60,000 MT of capacity, scaling Jubilant Ingrevia Limited’s overall annual Acetic Anhydride capacity to 210,000 MT
Several late-stage pipeline products have the potential to address some of these unmet needs
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
The meeting provides recommendations to the G20 and its Member States and international partners on the establishment of a R&D and manufacturing network for diagnostics
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
The combination will support clients in getting their end-to-end discovery and development programs delivered.
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
The survey inspected ambulances operating throughout the city
Science communication brings behavioural changes
ProBioGen previously developed the cell line and the manufacturing process and provided the initial clinical material for ImmunOs' innovative biologic.
The session took place in the presence of Union Ministers Hardeep Singh Puri and Gen V K Singh along with Anil Agarwal, Rajya Sabha Member of Parliament
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
CiRA, Kyoto University and Astellas - Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Subscribe To Our Newsletter & Stay Updated
